Morgan Stanley’s TScan Therapeutics TCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.24M | Buy |
853,346
+260,376
| +44% | +$378K | ﹤0.01% | 4994 |
|
|
2025
Q1 | $818K | Buy |
592,970
+180,112
| +44% | +$249K | ﹤0.01% | 5100 |
|
|
2024
Q4 | $1.26M | Buy |
412,858
+113,539
| +38% | +$345K | ﹤0.01% | 4972 |
|
|
2024
Q3 | $1.49M | Buy |
299,319
+57,647
| +24% | +$287K | ﹤0.01% | 4816 |
|
|
2024
Q2 | $1.41M | Buy |
241,672
+17,778
| +8% | +$104K | ﹤0.01% | 4777 |
|
|
2024
Q1 | $1.78M | Sell |
223,894
-245,512
| -52% | -$1.95M | ﹤0.01% | 4660 |
|
|
2023
Q4 | $2.74M | Buy |
469,406
+209,959
| +81% | +$1.22M | ﹤0.01% | 4757 |
|
|
2023
Q3 | $664K | Buy |
259,447
+150,972
| +139% | +$386K | ﹤0.01% | 5026 |
|
|
2023
Q2 | $271K | Sell |
108,475
-22,844
| -17% | -$57.1K | ﹤0.01% | 5510 |
|
|
2023
Q1 | $276K | Buy |
131,319
+89,144
| +211% | +$187K | ﹤0.01% | 5557 |
|
|
2022
Q4 | $65.4K | Sell |
42,175
-22,395
| -35% | -$34.7K | ﹤0.01% | 6170 |
|
|
2022
Q3 | $197K | Buy |
64,570
+7,481
| +13% | +$22.8K | ﹤0.01% | 5733 |
|
|
2022
Q2 | $180K | Buy |
57,089
+18,013
| +46% | +$56.8K | ﹤0.01% | 5956 |
|
|
2022
Q1 | $110K | Buy |
39,076
+11,672
| +43% | +$32.9K | ﹤0.01% | 6251 |
|
|
2021
Q4 | $123K | Sell |
27,404
-832
| -3% | -$3.73K | ﹤0.01% | 6317 |
|
|
2021
Q3 | $235K | Buy |
+28,236
| New | +$235K | ﹤0.01% | 5908 |
|